Medicus Pharma (TSX-V:MDCX) announced that it has filed a final short-form base shelf prospectus which will allow the company to offer up to US$50 million in securities over 25 months.
The company said that the shelf prospectus will allow it from time to time to offer shares, preferred shares, warrants, subscription receipts, debt securities, and units comprised of more than one of the foregoing securities or any combination of them in all of the provinces and territories in Canada.
It said it has no immediate plans to undertake an offering of securities but it has filed the shelf prospectus to maintain financial flexibility.
Should Medicus decide to offer any securities during the 25-month effective period, the specific terms will be set out in a supplementary prospectus.
Medicus Pharma (TSX-V:MDCX) is a clinical-stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and biotechnology companies through Food and Drug Administration (FDA) approved clinical trials.